Jilin Jian Yisheng Pharmaceutical Co Ltd (SHE:002566) — Market Cap & Net Worth
Market Cap & Net Worth: Jilin Jian Yisheng Pharmaceutical Co Ltd (002566)
Jilin Jian Yisheng Pharmaceutical Co Ltd (SHE:002566) has a market capitalization of $328.83 Million (CN¥2.25 Billion) as of September 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #14434 globally and #4288 in its home market, demonstrating a -3.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jilin Jian Yisheng Pharmaceutical Co Ltd's stock price CN¥6.79 by its total outstanding shares 330951600 (330.95 Million). Also see how large is Jilin Jian Yisheng Pharmaceutical Co Ltd's balance sheet for a full breakdown of the balance sheet.
Jilin Jian Yisheng Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Jilin Jian Yisheng Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $751.81 Million to $328.83 Million (-6.72% CAGR). Also see 002566 cash flow conversion for how efficiently the company converts equity into cash flow.
Jilin Jian Yisheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jilin Jian Yisheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Jilin Jian Yisheng Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.58x
Jilin Jian Yisheng Pharmaceutical Co Ltd's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.74x
Jilin Jian Yisheng Pharmaceutical Co Ltd's market cap is 12.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $590.38 Million | $939.01 Million | $13.19 Million | 0.63x | 44.74x |
| 2017 | $403.12 Million | $1.03 Billion | $60.07 Million | 0.39x | 6.71x |
| 2018 | $266.67 Million | $975.09 Million | $69.08 Million | 0.27x | 3.86x |
| 2019 | $309.88 Million | $1.01 Billion | $76.60 Million | 0.31x | 4.05x |
| 2020 | $311.64 Million | $842.59 Million | $80.06 Million | 0.37x | 3.89x |
| 2021 | $424.44 Million | $877.93 Million | $96.02 Million | 0.48x | 4.42x |
| 2022 | $381.78 Million | $830.04 Million | $83.10 Million | 0.46x | 4.59x |
| 2023 | $422.50 Million | $853.66 Million | $94.73 Million | 0.49x | 4.46x |
| 2024 | $330.28 Million | $668.47 Million | $52.09 Million | 0.49x | 6.34x |
| 2025 | $369.51 Million | $640.17 Million | $29.00 Million | 0.58x | 12.74x |
Competitor Companies of 002566 by Market Capitalization
Companies near Jilin Jian Yisheng Pharmaceutical Co Ltd in the global market cap rankings as of September 17, 2026. Review 002566 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Jilin Jian Yisheng Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Jilin Jian Yisheng Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jilin Jian Yisheng Pharmaceutical Co Ltd's market cap moved from $751.81 Million to $ 328.83 Million, with a yearly change of -6.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥328.83 Million | -11.01% |
| 2025 | CN¥369.51 Million | +11.88% |
| 2024 | CN¥330.28 Million | -21.83% |
| 2023 | CN¥422.50 Million | +10.66% |
| 2022 | CN¥381.78 Million | -10.05% |
| 2021 | CN¥424.44 Million | +36.20% |
| 2020 | CN¥311.64 Million | +0.57% |
| 2019 | CN¥309.88 Million | +16.20% |
| 2018 | CN¥266.67 Million | -33.85% |
| 2017 | CN¥403.12 Million | -31.72% |
| 2016 | CN¥590.38 Million | -21.47% |
| 2015 | CN¥751.81 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Jilin Jian Yisheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $328.83 Million USD |
| MoneyControl | $328.83 Million USD |
| MarketWatch | $328.83 Million USD |
| marketcap.company | $328.83 Million USD |
| Reuters | $328.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jilin Jian Yisheng Pharmaceutical Co Ltd
Jilin Jian Yisheng Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, wholesale, retail, import, and export of pharmaceutical products in China. The company offers paper packaging products; drugs comprising capsules, injections, tablets, granules, and other drug products; cosmetics; ginseng products; bee products; and food products comprisi… Read more